Is the PANSS used correctly? A systematic review

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Obermeier, Michael ^a   Schennach Wolff, Rebecca ^a   Meyer, Sebastian ^a   Möller, Hans Jürgen ^a   Riedel, Michael ^a,b   Krause, Daniela ^a   Seemüller, Florian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Vinzenz von Paul Hospital   (Germany)

Author keywords

Literature search; PANSS; Scale level

Indexed keywords

ARTICLE; CALCULATION; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; SYSTEMATIC REVIEW; PSYCHOLOGICAL RATING SCALE; REVIEW; STATISTICS;

HUMANS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 79960562870     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-113     Document Type: Article

References (46)

1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
2. Obermeier M, Mayr A, Schennach-Wolff R, Seemuller F, Moller HJ, Riedel M. Should the PANSS Be Rescaled?. Schizophr Bull 2010, 36:455-460. 10.1093/schbul/sbp124, 2879676, 19889950.
3. Leucht S, Kissling W, Davis JM. The PANSS Should Be Rescaled. Schizophr Bull 2010, 36:461-462. 10.1093/schbul/sbq016, 2879684, 20357133.
4. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007, 32:1903-1910. 10.1038/sj.npp.1301325, 17287825.
5. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 2009, 7-14.
6. FDA Application No.:021253. FDA. FDA 2004, Ref Type: Electronic Citation, FDA., http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21253_Zyprexa.TOC.cfm
7. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535. 10.1136/bmj.b2535, 2714657, 19622551.
8. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999, 56:29-36. 10.1001/archpsyc.56.1.29, 9892253.
9. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002, 59:441-448. 10.1001/archpsyc.59.5.441, 11982448.
10. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006, 163:743-745. 10.1176/appi.ajp.163.4.743, 16585455.
11. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008, 165:1420-1431. 10.1176/appi.ajp.2008.08050756, 18794207.
12. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007, 62:1363-1370. 10.1016/j.biopsych.2007.01.017, 17601495.
13. Campbell DB, Ebert PJ, Skelly T, Stroup TS, Lieberman J, Levitt P, et al. Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biol Psychiatry 2008, 63:32-41. 10.1016/j.biopsych.2007.04.018, 2194758, 17588543.
14. Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 2008, 33:3111-3125. 10.1038/npp.2008.33, 18418366.
15. Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 2002, 27:1071-1081. 10.1016/S0893-133X(02)00375-5, 12464464.
16. Kinon BJ, Chen L, scher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35:581-590. 10.1038/npp.2009.164, 3055392, 19890258.
17. Levine SZ, Rabinowitz J. Trajectories and Antecedents of Treatment Response Over Time in Early-Episode Psychosis. Schizophr Bull 2008,
18. Haas M, Eerdekens M, Kushner S, Singer J, Augustyns I, Quiroz J, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry 2009, 194:158-164. 10.1192/bjp.bp.107.046177, 19182179.
19. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995, 166:712-726. 10.1192/bjp.166.6.712, 7545060.
20. Schennach-Wolff R, Seemuller FH, Mayr A, Maier W, Klingberg S, Heuser I, et al. An early improvement threshold to predict response and remission in first-episode schizophrenia. Br J Psychiatry 2010, 196:460-466. 10.1192/bjp.bp.109.069328, 20513856.
21. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003, 64:1250-1257. 10.4088/JCP.v64n1017, 14658976.
22. Volpi S, Potkin SG, Malhotra AK, Licamele L, Lavedan C. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009, 70:801-809. 10.4088/JCP.08m04391, 19573479.
23. Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, Turkoz I, Carothers J, Bossie CA, et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry 2010, 71:587-598. 10.4088/JCP.09m05564yel, 20492853.
24. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008, 69:817-829. 10.4088/JCP.v69n0515, 18466043.
25. Glick ID, Poyurovsky M, Ivanova O, Koran LM. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. J Clin Psychiatry 2008, 69:1856-1859. 10.4088/JCP.v69n1202, 19026264.
26. Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007, 68:832-842. 10.4088/JCP.v68n0603, 17592906.
27. Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry 2007, 68:29-36. 10.4088/JCP.v68n0104, 17764382.
28. Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 2006, 67:1093-1103. 10.4088/JCP.v67n0712, 16889453.
29. nil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005, 66:63-72. 10.4088/JCP.v66n0109, 15669890.
30. Lane HY, Chang YC, Cheng YC, Liu GC, Lin XR, Chang WH. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry 2003, 64:316-320. 10.4088/JCP.v64n0314, 12716274.
31. Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, et al. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J Clin Psychiatry 2002, 63:931-935. 10.4088/JCP.v63n1011, 12416603.
32. Emsley RA, Roberts MC, Rataemane S, Pretorius J, Oosthuizen PP, Turner J, et al. Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. J Clin Psychiatry 2002, 63:9-14. 10.4088/JCP.v63n0103, 12562113.
33. Dossenbach MR, Kratky P, Schneidman M, Grundy SL, Metcalfe S, Tollefson GD, et al. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry 2001, 62(Suppl 2):28-34.
34. Lindenmayer JP, Iskander A, Park M, Apergi FS, Czobor P, Smith R, et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry 1998, 59:521-527. 10.4088/JCP.v59n1005, 9818633.
35. Koenigsberg HW, Reynolds D, Goodman M, New AS, Mitropoulou V, Trestman RL, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003, 64:628-634. 10.4088/JCP.v64n0602, 12823075.
36. Case M, Stauffer VL, scher-Svanum H, Conley R, Kapur S, Kane JM, et al. The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychol Med 2010, 1-10.
37. Mizrahi R, Korostil M, Starkstein SE, Zipursky RB, Kapur S. The effect of antipsychotic treatment on Theory of Mind. Psychol Med 2007, 37:595-601. 10.1017/S0033291706009342, 17094815.
38. Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med 2000, 30:95-105. 10.1017/S0033291799001476, 10722180.
39. Musil R, Spellmann I, Riedel M, Dehning S, Douhet A, Maino K, et al. SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. J Psychiatr Res 2008, 42:963-970. 10.1016/j.jpsychires.2007.11.003, 18191416.
40. Lipkovich I, Deberdt W, Csernansky JG, Buckley P, Peuskens J, Kollack-Walker S, et al. Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy. J Psychiatr Res 2007, 41:305-310. 10.1016/j.jpsychires.2006.07.016, 17010994.
41. Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 2008, 42:89-97. 10.1016/j.jpsychires.2006.10.002, 17113599.
42. Prikryl R, Ceskova E, Kasparek T, Kucerova H. Neurological soft signs, clinical symptoms and treatment reactivity in patients suffering from first episode schizophrenia. J Psychiatr Res 2006, 40:141-146. 10.1016/j.jpsychires.2005.03.008, 15907940.
43. Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002, 36:7-18. 10.1016/S0022-3956(01)00048-6, 11755456.
44. Girgis RR, Merrill DB, Vorel SR, Edward K, Kimberly P, You M, et al. Aripiprazole versus haloperidol treatment in early-stage schizophrenia. J Psychiatr Res 2010,
45. Giegling I, Drago A, Schafer M, Moller HJ, Rujescu D, Serretti A. Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J Psychiatr Res 2010, 44:487-492. 10.1016/j.jpsychires.2009.11.004, 19962159.
46. McEvoy JP, Daniel DG, Carson WH, McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007, 41:895-905. 10.1016/j.jpsychires.2007.05.002, 17631314.